LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio

LabCorp’s DoseASSURE® Portfolio Provides Most Expansive Biologics TDM
Menu Combined with Expert Guidance

BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp® (NYSE: LH), a leading global life sciences company that is
deeply integrated in guiding patient care, today announced a new assay
in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio. The new
Certolizumab Concentration and Anti-Certolizumab Antibody DoseASSURE™
CTZ assay, helps physicians monitor individual drug response for
patients who are on Certolizumab, a biologic drug used to treat certain
inflammatory diseases, such as rheumatoid arthritis and Crohn’s disease.

Biologic drugs are complex, protein-based therapies that can be used to
treat certain inflammatory diseases and are among the fastest growing
class of drugs available today. However, the expense of these
medications and the variability in patient response can present numerous
challenges. LabCorp’s DoseASSURE® portfolio helps address these
challenges by providing quantitative, patient-specific measurement which
can guide patient therapy. With the launch of the DoseASSURE CTZ,
LabCorp now has the most comprehensive biologics TDM menu in the
industry, targeting the largest number of biologic drugs.

“Biologic drugs can be life-changing, but individual patient response to
biologics can vary greatly,” said David P. King, LabCorp’s chairman and
CEO. “LabCorp’s DoseASSURE portfolio helps to deliver on the promise of
precision medicine by enabling more effective and more individualized
treatment plans that can improve clinical outcomes at reduced costs.”

Studies demonstrate the use of TDM can improve efficacy and prolong
successful response to biologic treatment. Accordingly, appropriate use
of TDM can diminish the need for disease-related surgery and
hospitalization by reducing the risk of treatment failure.

“Our expanding DoseASSURE portfolio demonstrates our commitment to
providing world-class diagnostic and patient management solutions for
physicians and patients,” said Marcia Eisenberg, Ph.D., chief scientific
officer of LabCorp Diagnostics. “LabCorp adds value because our
diagnostics expertise and available clinical decision support tools help
clinicians integrate biologic drugs and the associated diagnostics into
optimal patient care.”

DoseASSURE® TDM Portfolio

LabCorp’s TDM DoseASSURE portfolio includes eight assays measuring 10
biologic therapies — including Adalimumab, Infliximab, Infliximab-dyyb,
Infliximab-abda, Etanercept, Rituximab, Golimumab, Vedolizumab,
Ustekinumab, and Certolizumab.

  • Adalimumab and Anti-Adalimumab Antibody, DoseASSURE™ ADL
  • Certolizumab and Anti-Certolizumab Antibody, DoseASSURE™ CTZ
  • Etanercept and Anti-Etanercept Antibody, DoseASSURE™ ETN
  • Golimumab and Anti-Golimumab Antibody, DoseASSURE™ GOL
  • Infliximab and Anti-Infliximab Antibody, DoseASSURE™ IFX
  • Rituximab and Anti-Rituximab Antibody, DoseASSURE™ RTX
  • Ustekinumab and Anti-Ustekinumab Antibody, DoseASSURE™ UST
  • Vedolizumab and Anti-Vedolizumab Antibody, DoseASSURE™ VDZ

For more information about LabCorp’s DoseASSURE portfolio, please visit
the online test menu at

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life
sciences company that is deeply integrated in guiding patient care,
providing comprehensive clinical laboratory and end-to-end drug
development services. With a mission to improve health and improve
lives, LabCorp delivers world-class diagnostic solutions, brings
innovative medicines to patients faster, and uses technology to improve
the delivery of care. LabCorp reported revenues of more than $11 billion
in 2018. To learn more about LabCorp, visit,
and to learn more about Covance Drug Development, visit

Forward-Looking Statements

This press release contains forward-looking statements including but
not limited to statements with respect to diagnostic solutions, the
impact of various factors on operating and financial results, and the
opportunities for future growth. Each of the forward-looking statements
is subject to change based on various important factors, including
without limitation, competitive actions and other unforeseen changes and
general uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing decisions,
including changes in payer regulations or policies, other adverse
actions of governmental and third-party payers, changes in testing
guidelines or recommendations, adverse results in material litigation
matters, the impact of changes in tax laws and regulations, failure to
maintain or develop customer relationships, our ability to develop or
acquire new products and adapt to technological changes, failure in
information technology, systems or data security, employee relations,
and the effect of exchange rate fluctuations. Actual results could
differ materially from those suggested by these forward-looking
statements. The Company has no obligation to provide any updates to
these forward-looking statements even if its expectations change.
Further information on potential factors, risks and uncertainties that
could affect operating and financial results is included in the
Company’s Form 10-K for the year ended Dec. 31, 2017, and subsequent
Forms 10-Q, including in each case under the heading RISK FACTORS, and
in the Company’s other filings with the SEC. The information in this
press release should be read in conjunction with a review of the
Company’s filings with the SEC including the information in the
Company’s Form 10-K for the year ended Dec. 31, 2017, and subsequent


LabCorp Contacts:
Media: Donald Von Hagen — 336-436-8263
Clarissa Willett — 336-436-5076

error: Content is protected !!